In a recent interview with Drug Discovery News, Dale Levitzke, CEO of Sphere Bio, shares how the company’s evolution – and its breakthrough picodroplet microfluidic platforms – are driving the future of single-cell analysis, antibody discovery, and cell therapy development.

As biotherapeutics development becomes increasingly complex, researchers are demanding tools that combine speed, precision, and scalability. Sphere Bio, formerly Sphere Fluidics, has rebranded to reflect its transformation from a microfluidics innovator into a commercial provider of integrated life science tools.

At the heart of this evolution is the company’s proprietary picodroplet technology, which powers its flagship Cyto-Mine^® and next-generation Cyto-Mine^® Chroma platforms, enabling researchers to perform high-throughput, single-cell functional assays with unparalleled resolution.

✅ The rebranding reflects commercial expansion, positioning Sphere Bio as a fully-integrated life science tools company.

✅ Cyto-Mine^® Chroma enables multiplexed single-cell assays, including secretion profiling, binding specificity, and viability—within one run.

✅ Picodroplet technology enables high-resolution functional screening, reducing discovery timelines and improving downstream outcomes in biologics and cell therapy.

For more insights on the latest developments in biologics and cell line research, visit Sphere Bio’s Knowledge Hub or or dive into our Cyto-Mine® Chroma solution for early-stage screening.

This article is part of our Editorial Coverage series, showcasing Sphere Bio’s thought leadership and technological contributions in top-tier industry publications. Stay tuned for more.